Transgender communities face inordinate challenges, but receive a small slice of philanthropic funding. With a new grantmaking program that draws on input from the trans community, Gilead Sciences is helping to change that.
Barry Sternlicht set up a foundation early last decade with his former wife. His adult children now help drive family giving, which includes issues like education reform and diabetes research. Sternlicht talks to us about his journey.
Most health philanthropy consists of chasing breakthrough cures and treatments. But what many ill people want is improved quality of life—which is why two funders recently launched a campaign to raise awareness of the benefits of palliative care.
Over the past 18 months, the Wellcome Trust has wrestled with how to respond to growing critiques that philanthropy is at odds with democracy. A top executive at the foundation—which has assets of $30 billion—explains where it came out.
The Levi Strauss Foundation, an early funder in the fight against HIV/AIDS, continues to step up in changing times, meeting a roll-back of hard fought gains in the areas of diversity and inclusion with expanded support for the trans community.
More than $14 million in recent grants to establish a network of research teams focused on sudden cardiac arrest and heart arrhythmias shows that the American Heart Association is taking on a greater role in setting research priorities.
Gilead Sciences is a leading player in HIV/AIDS funding in the U.S. South, with a major grantmaking program aimed at tackling an epidemic that’s still raging in this part of the country. Where’s the money going?
The Starr Foundation has been investing in stem cell research for 14 years and recently doubled down on a major collaboration in New York City, to which it’s now committed $150 million. What’s been achieved so far by this effort? And what lies ahead?
Corporate philanthropy has been changing as more companies align their giving with their mission and get more strategic. A report looks at how this trend is playing out in the health and life sciences industry—and the potential for these firms to have far greater impact.
The latest installment in the higher ed artificial intelligence gold rush finds a corporate funder backing new research on health and AI. Other campus donors will likely follow, even as some experts warn that this new technology could exacerbate health inequities.
Gene editing technologies have broad potential in medicine. Late last year, the Bill & Melinda Gates Foundation awarded Boston Children’s Hospital a $1.5 million grant to expand gene therapies for sickle cell disease in developing countries.
In 2016, the tech billionaire Sean Parker launched the Parker Institute for Cancer Immunotherapy with a $250 million investment. We check in with the institute’s Chief Science Officer to see how things are going and what’s been accomplished so far.
We’ve tracked nearly $80 million in new commitments for cancer research so far this year. With funders keen to leverage limited resources for maximum impact, a majority of that giving has gone to underfunded forms of cancer and young investigators.
Using genomics to design far more precise and effective medical treatment plans has been called the “wave of the future.” Now, as breakthroughs increase, more funders are coming to the table to back biomedical research in this emerging field.
Boehringer Ingelheim and its BI Cares Foundation make a lot of grants in Connecticut, but also to researchers nationwide. What healthcare access, STEM, and research programs does this pharmaceutical giant back?
A $10 million gift from the Belford Family Trust will establish a specialized Spinal Cord Injury Center at Ohio State. It comes at a time when funding needs to keep up with growing promise of therapeutic breakthroughs.
Pancreatic cancer often has a grim prognosis, typically evading early detection, and is difficult to treat. Three foundations are determined to change that with research grants for early detection and treatment of the disease.
A common theme of Len Blavatnik’s giving is an eagerness to support promising areas of medical research. Still, his biggest gift yet—$200 million to Harvard Medical School—has raised the usual questions about big philanthropy.
As Alzheimer’s disease inflicts an ever-rising toll on aging populations in the U.S. and overseas, the race is on for research breakthroughs. The Rainwater Charitable Foundation recently announced a major new prize focused on a key protein.
Diagnostic errors are the most common cause of medical errors, causing an estimated 40,000 to 80,000 deaths per year. But there is little funding for research on this problem. The Gordon and Betty Moore Foundation is looking to change that.
No mere “skin problem,” psoriasis is an incurable autoimmune disease afflicting 125 million people worldwide, carrying social and psychological impacts, and even the potential to shorten lifespans. But money for research is hard to come by. Who’s helping?
More deep-pocketed funders are interested in the age-old quest to live forever, in one form or another. We dig into the interesting story of Terasem Movement Foundation, founded by tech couple Martine and Bina Rothblatt.
Funding for rare diseases rarely comes from foundations or billionaire donors. Instead, it mostly comes from the families and friends of people affected. Here’s an example of how a small community of donors can underwrite significant research.
It’s hard to overstate the importance of patient private funding in the battle against Parkinson’s. Grantmakers in it for the long haul have often been behind gains made against the disease, with such successes now coming at a faster clip.
Paul Allen, who died recently, exemplified the best of big philanthropy. He embraced risk taking and cared deeply, journeying to the outer frontiers of scientific knowledge and to the front lines of the world’s biggest challenges. IP editor David Callahan assesses his legacy.
Susan G. Komen recently announced grants of $26 million to fund 62 new research projects that address some of the most difficult breast cancer cases. After years of troubles, this important funder has bounced back in a big way.
Helmsley Charitable Trust and Chan Zuckerberg Initiative, two heavy hitters in health research, are partnering to better understand cells in our intestines, as part of a larger moonshot project to catalogue all human cells.
The Muscular Dystrophy Association is the leading funder taking on this disease. We look at its recent research grants—and where the battle against MD now stands after decades of research.
Despite being one of the leading killers of men, claiming nearly 30,000 lives a year, prostate cancer research is seriously underfunded. Two grantmakers are leading the charge, but they can’t do it alone.
It’s not often that we see funders pooling money to create a not-for-profit generic drug company. In fact, we’ve never seen it before. Which is why the creation of Civica Rx deserves a close look.